文献速递乳腺USMR

乳腺癌患者新辅助化疗期间及之后通过超声和MRI监测预测腋窝反应

Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients.
PubMed 文献 · Eur Radiol · 2019-12-04

研究纳入131例临床腋窝淋巴结阳性并接受新辅助化疗及手术的乳腺癌患者,在化疗前、中、后行超声和3.0 T-MR检查,分析腋窝淋巴结特征和肿瘤大小对术后腋窝淋巴结状态的预测价值。术后60例(45.8%)淋巴结阳性,化疗中期超声联合肿瘤大小和皮质厚度诊断性能最佳(AUC 0.760)。监测超声和MR腋窝淋巴结及肿瘤大小有助于预测新辅助化疗的腋窝反应。

要点

  • 化疗中期超声测量的肿瘤大小和皮质厚度联合诊断腋窝淋巴结阳性的AUC最高(0.760)。
  • 化疗前MR肿瘤大小、化疗中期超声肿瘤大小和皮质厚度、化疗后MR肿瘤大小和皮质厚度与新辅助化疗后腋窝淋巴结阳性独立相关。
  • 化疗期间监测腋窝淋巴结形态学特征和肿瘤大小有助于预测腋窝反应。

关键影像表现/征象

  • 化疗前超声和MR肿瘤大小在术后淋巴结阳性组与阴性组间差异有统计学意义(p < 0.01)。
  • 化疗中期和化疗后超声淋巴结数目、皮质厚度、肿瘤大小及肿瘤大小缩小率,以及化疗中期和化疗后MR皮质厚度、门结构、肿瘤大小及肿瘤大小缩小率、化疗后MR直径比在两组间差异有统计学意义(p < 0.03)。

诊断标准与关键数值

  • 多因素分析显示,化疗前MR肿瘤大小(OR 1.03)、化疗中期超声肿瘤大小(OR 1.05)和皮质厚度(OR 1.53)、化疗后MR肿瘤大小(OR 1.06)和皮质厚度(OR 1.64)与腋窝淋巴结阳性独立相关(p < 0.004)。
  • 化疗中期超声肿瘤大小联合皮质厚度诊断性能最佳,AUC为0.760。

临床应用与阅片要点

  • 阅片时可关注化疗中期超声测量的肿瘤大小和皮质厚度,二者联合对预测腋窝淋巴结阳性具有最高诊断性能(AUC 0.760)。
  • 化疗前MR肿瘤大小、化疗中期超声肿瘤大小和皮质厚度、化疗后MR肿瘤大小和皮质厚度可作为预测腋窝反应的影像指标。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To investigate whether monitoring with ultrasound and MR imaging before, during and after neoadjuvant chemotherapy (NAC) can predict axillary response in breast cancer patients.

MATERIALS AND METHODS: A total of 131 breast cancer patients with clinically positive axillary lymph node (LN) who underwent NAC and subsequent surgery were enrolled. They had ultrasound and 3.0 T-MR examinations before, during and after NAC. After reviewing ultrasound and MR images, axillary LN features and tumour size (T size) were noted. According to LN status after surgery, imaging features and their diagnostic performances were analysed.

RESULTS: Of the 131 patients, 60 (45.8%) had positive LNs after surgery. Pre-NAC T size at ultrasound and MR was different in positive LN status after surgery (p < 0.01). There were significant differences in mid- and post-NAC number, cortical thickness (CxT), T size and T size reduction at ultrasound and mid- and post-NAC CxT, hilum, T size and T size reduction, and post-NAC ratio of diameter at MR (p < 0.03). On multivariate analysis, pre-NAC MR T size (OR, 1.03), mid-NAC ultrasound T size (OR, 1.05) and CxT (OR, 1.53), and post-NAC MR T size (OR, 1.06) and CxT (OR, 1.64) were independently associated with positive LN (p < 0.004). Combined mid-NAC ultrasound T size and CxT showed the best diagnostic performance with AUC of 0.760.

CONCLUSION: Monitoring ultrasound and MR axillary LNs and T size can be useful to predict axillary response to NAC in breast cancer patients.

KEY POINTS: • Monitoring morphologic features of LNs is useful to predict axillary response. • Monitoring tumour size by imaging is useful to predict axillary response. • The axillary ultrasound during NAC showed the highest diagnostic performance.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Eun NL, Son EJ, Gweon HM, et al. Prediction of axillary response by monitoring with ultrasound and MRI during and after neoadjuvant chemotherapy in breast cancer patients. Eur Radiol. 2019. PMID: 31802216. doi:10.1007/s00330-019-06539-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。